Novartis Kymriah® demonstrates strong responses in
Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 ...
Source: globenewswire.com
📰 Medication Guide News
Page 51 - Medication Guide News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Medication Guide. Real-time updates on events, politics, business and more.
Novartis Pharma AG: Novartis Kymriah demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of approximately 17 months
Source: finanznachrichten.de
Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
/PRNewswire/ -- Novartis announced Kymriah® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular...
Source: prnewswire.com
Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
Source: investegate.co.uk
MorphoSys AG: MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies- Results from the retrospective cohort analysis indicate significant
United States Grzegorz Nowakowski Peter Langmuir Nuwan Kurukulasuriya Practice Research Clinical Haematology Janssen Biotech Inc
Source: finanznachrichten.de
A mother's life with lung cancer | Health & Wellness
(BPT) - While Lysa Buonanno was completing her training as a radiology technologist, she started experiencing intense back pain. Since her work often involved lifting and moving patients, she assumed
Source: rantoulpress.com
AbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S.
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced an update to the U.S. Prescribing Information and Medication Guide for RINVOQ® (upadacitinib) for the...
United States Michael Severino European Commission Drug Administration Exchange Commission Abbvie Inc
Source: prnewswire.com
AbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S.
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced an update to the U.S. Prescribing Information and Medication Guide for RINVOQ® (upadacitinib) for the...
United States Michael Severino European Commission Drug Administration Exchange Commission Abbvie Inc
Source: prnewswire.com
Galderma leads oral presentation on hyaluronic acid filler safety insights at ASDS 2021 Annual Meeting
/PRNewswire/ -- Galderma announced the presentation of data supporting its aesthetics portfolio and pipeline at the virtual American Society for Dermatologic...
Source: prnewswire.com
AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation.
United States Thomas Hudson Health Assessment Questionnaire American College Of Rheumatology Exchange Commission American College
Source: apnews.com